These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15718306)

  • 1. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Goetz MP; Toft D; Reid J; Ames M; Stensgard B; Safgren S; Adjei AA; Sloan J; Atherton P; Vasile V; Salazaar S; Adjei A; Croghan G; Erlichman C
    J Clin Oncol; 2005 Feb; 23(6):1078-87. PubMed ID: 15718306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
    Bagatell R; Gore L; Egorin MJ; Ho R; Heller G; Boucher N; Zuhowski EG; Whitlock JA; Hunger SP; Narendran A; Katzenstein HM; Arceci RJ; Boklan J; Herzog CE; Whitesell L; Ivy SP; Trippett TM
    Clin Cancer Res; 2007 Mar; 13(6):1783-8. PubMed ID: 17363533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.
    Nowakowski GS; McCollum AK; Ames MM; Mandrekar SJ; Reid JM; Adjei AA; Toft DO; Safgren SL; Erlichman C
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6087-93. PubMed ID: 17062684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
    Grem JL; Morrison G; Guo XD; Agnew E; Takimoto CH; Thomas R; Szabo E; Grochow L; Grollman F; Hamilton JM; Neckers L; Wilson RH
    J Clin Oncol; 2005 Mar; 23(9):1885-93. PubMed ID: 15774780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
    Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
    Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
    Banerji U; O'Donnell A; Scurr M; Pacey S; Stapleton S; Asad Y; Simmons L; Maloney A; Raynaud F; Campbell M; Walton M; Lakhani S; Kaye S; Workman P; Judson I
    J Clin Oncol; 2005 Jun; 23(18):4152-61. PubMed ID: 15961763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
    Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
    Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
    Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
    Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG; Stoller RG; Naret C; Guo J; Belani CP
    Clin Cancer Res; 2007 Mar; 13(6):1769-74. PubMed ID: 17363531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
    Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
    Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
    Iyer G; Morris MJ; Rathkopf D; Slovin SF; Steers M; Larson SM; Schwartz LH; Curley T; DeLaCruz A; Ye Q; Heller G; Egorin MJ; Ivy SP; Rosen N; Scher HI; Solit DB
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1089-97. PubMed ID: 22124669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
    Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
    Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
    Lancet JE; Gojo I; Burton M; Quinn M; Tighe SM; Kersey K; Zhong Z; Albitar MX; Bhalla K; Hannah AL; Baer MR
    Leukemia; 2010 Apr; 24(4):699-705. PubMed ID: 20111068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
    Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
    Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S
    Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.